A smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 349-359

  Selroos, Olof ^a,b  

^a SEMECO AB   (Sweden)

^b NONE   (Sweden)

Author keywords

Asthma control; Combination therapy; Inhaled corticosteroid; Long acting 2 agonist; Symbicort SMART (Symbicort Maintenance and Reliever Therapy)

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; SALBUTAMOL; STEROID; TERBUTALINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALER; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PULSE RATE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREMOR;

EID: 34250004849     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.349     Document Type: Review

References (70)

1. Aalbers R, Backer V, Kava KK, et al. 2004. Adjustable maintenance dosing with budesonide-formoterol compared with fixed-dose salmeterol-fluticasone in moderate to severe asthma. Curr Med Res Opin, 20:225-40.
2. 2-agonist or salmeterol-fluticasone propionate combination. Int J Clin Pract, 59:156-62.
3. Ankerst J, Persson G, Weibull E. 2003. Tolerability of a high dose of budesonide-formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther, 16:147-51.
4. 2-agonists and corticosteroids. Eur Respir J, 19:182-91.
5. Barnes PJ. 2007. Scientific rationale for using a single inhaler for asthma control. Eur Respir J, 29:587-95.
6. Bennett JA, Tattersfield AE. 1997. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax, 52:458-64.
7. Bisgaard H, LeRoux P, Bjåmer D, et al. 2006. Budesonide-formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest, 130:1733-43.
8. Boonsawat W, Charoenratanakul S, Pothiratana C, et al. 2003. Formoterol (Oxis®) Turbuhaler® as a rescue therapy compared with salbutamol by pMDI plus spacer in patients with acute severe asthma. Respir Med, 97:1067-74.
9. Boushey HA, Sorkness CA, King TS, et al. 2005. Daily versus as needed corticosteroids for mild persistent asthma. N Engl J Med, 352:519-28.
10. Buhl R, Kardos P, Richter K, et al. 2004. The effect of adjustable dosing with budesonide-formoterol on health-related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin, 20:1209-29.
11. Busse WW, Chervinsky F, Condemi J, et al. 1998. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol, 101:457-63.
12. Canonica GW, Castellani P, Cazzola M, et al. 2004. Adjustable maintenance dosing with budesonide-formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm Pharmacol Ther, 17:239-47.
13. Ellul-Micallef R, Johansson S-A. 1983. Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Br J Clin Pharmacol, 115:419-22.
14. FitzGerald JM, Sears MR, Boulet L-P, et al. 2003. Adjustable maintenance dosing with budesonide-formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J, 10:427-34.
15. FitzGerald JM, Becker A, Sears MR, et al. 2004. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax, 59:550-6.
16. FitzGerald JM, Boulet L-P, Follows RMA. 2005. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol-fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther, 27:393-406.
17. Foresi A, Morelli MC, Catena E. 2000. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest, 117:440-6.
18. Garrett J, Williams S. Wong C, et al. 1998. Treatment of acute exacerbations with an increased dose of inhaled steroid. Arch Dis Child, 79:12-17.
19. Gibson PG, Saltos N, Fakes K. 2001. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med, 163:32-6.
20. Gibson PG. 2005. Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur Respir J, 25:397-9.
21. Guhan AR, Cooper S, Oborne J, et al. 2000. Systemic effects of formoterol and salmeterol : a dose-response comparison in healthy subjects. Thorax, 55:650-6.
22. Haahtela T, Järvinen M, Kava T, et al. 1994. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med, 331:700-5.
23. Haahtela T, Tuomisto LE, Pietinalho A, et al. 2006. A 10 year asthma programme in Finland: major change for the better. Thorax, 61:663-70.
24. Haque RA, Johnson M, Adcock IM, et al. 2006. Addition of salmeterol to fluticasone prolongs retention of glucocorticoid receptors within the nucleus of BEAS-2B cells and enhances downstream glucocorticoid effects. Proc Am Thorac Soc, 3:A78.
25. Harrison TW, Oborne J, Newton S, et al. 2004. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet, 363:271-5.
26. Haughney J, Barnes G, Partridge M, et al. 2004. The living and breathing study: a study of patients' views of asthma and its treatments. Prim Care Resp J, 13:28-35.
27. Haughney J, Fletcher M, Wolfe S, et al. 2006. Features of asthma management: quantifying the patient's perspective using discrete choice modelling. Eur Respir J, 28(suppl 50):122s.
28. Holt S, Ryder-Lewis S, Masoli M, et al. 2005. Fixed and adjustable dose asthma action plans based on combination therapy: a pilot study. Respirology, 10:497-503.
29. Hyland ME, Ståhl E. 2004. Asthma treatment needs: a comparison of patients' and health care professionals' perceptions. Clin Ther, 26:2141-52.
30. Ind PW, Haughney J, Price D, et al. 2004. Adjustable and fixed dosing with budesonide-formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med, 98:464-75.
31. Jatakanon A, Lim S, Barnes PJ. 2000. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med, 161:64-72.
32. Juniper EF, O'Byrne PM, Guyatt GH, et al. 1999. Development and validation of questionnaire to measure asthma control. Eur Respir J, 14:902-7.
33. Juniper EF, Svensson K, Mörk A-C, et al. 2005. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med, 99:553-8.
34. Kuna P, Peters J, Buhl R. 2006. Budesonide-formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide-formoterol or salmeterol-fluticasone. Eur Respir J, 28(suppl 50):205s.
35. Leuppi JD, Salzberg M, Meyer L, et al. 2003. An individualized, adjustable maintenance regimen of budesonide-formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly, 133:302-9.
36. Lundborg M, Wille S, Bjermer L, et al. 2005. Maintenance plus reliever budesonide-formoterol compared with a higher maintenance dose of budesonide-formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin, 22:809-21.
37. Malolepszy J, Böszörményi Nagy G, Selroos O, et al. 2001. Safety of formoterol Turbuhaler at cumulative doses of 90 g in patients with acute bronchial obstruction. Eur Respir J, 18:928-34.
38. Maneechotesuwan K, Usmani OS, Adcock IM, et al. 2002. The modulation of GATA-3 nuclear localization by fluticasone & salmeterol. Am J Respir Crit Care Med, 165:A616.
39. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. 2005. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest, 128:1936-42.
40. 2-agonists. Curr Pharmaceut Design, 12:3261-79.
41. [NIH GINA] National Institutes of Health, Global Initiative for Asthma. 2006. Global strategy for asthma management and prevention [online]. Accessed December 2006. URL: http://www.ginasthma.org/. NIH Publication No 02-3659, Bethesda, MD, 1995 (updated 2006).
42. O'Byrne PM, Barnes PJ, Rodriguez-Rousin R, et al. 2001. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trail. Am J Respir Crit Care Med, 164:1392-7.
43. O'Byrne PM. 2005. Daily inhaled corticosteroid treatment should be prescribed for mild persistent asthma. Am J Respir Crit Care Med, 172:410-12.
44. O'Byrne PM, Bisgaard H, Godard PP, et al. 2005. Budesonide-formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 171:129-36.
45. Palmqvist M, Persson G, Lazer L, et al. 1997. Inhaled dry-powder formoterol and salmeterol in asthmatic patients; onset of action, duration of effect and potency. Eur Respir J, 10:2484-9.
46. Palmqvist M, Ibsen T, Mellen A, et al. 1999. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med, 160:244-9.
47. Palmqvist M, Arvidsson P, Beckman O, et al. 2001. Onset of bronchodilation of budesonide-formoterol vs. salmeterol-fluticasone in single inhalers. Pulm Pharmacol Ther, 14:29-34.
48. Partridge M, van der Molen T, Myrseth S-E, et al. 2006. Attitudes and actions of asthma patients on regular maintenance therapy: The INSPIRE study. BMC Pulm Med, 6:13.
49. Pauwels RA, Löfdahl C-G, Postma DS, et al. 1997. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med, 337:1405-11.
50. Politiek MJ, Boorsma M, Aalbers R. 1999. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J, 13:988-92.
51. Rabe KF, Vermeire PA, Soriano JB, et al. 2000. Clinical management of asthma in 1999: the Asthma Insight and Reality in Europe (AIRE) study. Eur Respir J, 16:802-7.
52. Rabe KF, Adachi M, Lai CKW, et al. 2004. Worldwide severity and control of asthma in children and adults: the global Asthma Insight and Reality surveys. J Allergy Clin Immunol, 114:40-7.
53. Rabe KF, Pizzichini E, Ställberg B, et al. 2006. Budesonide-formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double-blind trial. Chest, 129:246-56.
54. Rabe KF, Atienza T, Magyar P, et al. 2006. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet, 368:744-53.
55. Ringdal N, Derom E, Wåhlin-Boll E, et al. 1998. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med, 92:1017-21.
56. Rosenborg J, Bengtsson T, Larsson P, et al. 2000. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol, 56:363-70.
57. Rosenborg J, Larsson P, Rott Z, et al. 2002. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med, 96:412-17.
58. Rosenhall L, Heinig JH, Lindqvist A, et al. 2002. Budesonide-formoterol (Symbicort®) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract, 56:427-33.
59. Rosenhall L, ElvstrandA, Tilling B, et al. 2003. One-year safety and efficacy of budesonide-formoterol in a single inhaler (Symbicort® Turbuhaler®) for the treatment of asthma. Respir Med, 97:702-8.
60. Rubinfeld AR, Scicchitano R, Hunt A, et al. 2006. Formoterol Turbuhaler® as reliever medication in patients with acute asthma. Eur Respir J, 27:735-41.
61. Scicchitano R, Aalbers R, Ukena D, et al. 2004. Efficacy and safety of budesonide-formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin, 20:1403-18.
62. Seberová E, Andersson A. 2000. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by pMDI. Respir Med, 94:607-11.
63. Ställberg B, Olsson P, Jörgensen LA, et al. 2003. Budesonide-formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract, 57:656-61.
64. Tötterman KJ, Huhti L, Sutinen E, et al. 1998. Tolerability of high doses of formoterol and terbutaline via Turbuhaler® for 3 days in stable asthmatic patients. Eur Respir J, 12:573-9.
65. Tsai YG, Lee MY, Yang KD, et al. 2001. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Pediatr, 139:433-7.
66. Ullman A, Svedmyr N. 1988. Salmeterol, a new long acting inhaled beta2adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax, 43:674-8.
67. Usmani OS, Ito K, Maneechotesuwan K, et al. 2005. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med, 172:704-12.
68. van der Woude HJ, Boorsma M, Bergqvist PBF, et al. 2004. Budesonide-formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther, 17:89-95.
69. Vogelmeier C, D'Urzo A, Pauwels R, et al. 2005. Budesonide-formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J, 26:819-28.
70. Zetterström O, Buhl R, Mellem H, et al. 2001. Improved asthma control with budesonide-formoterol in a single inhaler, compared with budesonide alone. Eur Respir J, 18:262-8.